MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: Thekla

madmax darf es ..dann durfen wir auch ...

Eine Runde 🥛🥃🍾🍸🚬

Gude wie…souR

🥛

🔔 1️⃣🐒4️⃣7️⃣ 🔔

Guude.. dann bitte durch da und Volumenanstieg. Es wird Zeit!

Schaffen wir heute ….und dann wird’s spannend …..wie sagen die gingen Leute heutzutage……Save 😂😉

@tomy im logarithmischen Chart bei 170 Dollar heute?

🔔 1️⃣4️⃣6️⃣ 🔔 ich wollte auch mal wieder bimmeln. Gebe auch einen 🐒4️⃣7️⃣aus 😉

Wo genau sitzt die Oberkante des Abwärtskanals seit Anfang Februar ? 148€ ?

🔔1️⃣4️⃣5️⃣🔔

UPS keiner konnte Sie Verstehen

Sind die Marsianer gelandet und fragen nach Impfstoff

IamtheEye da gibt es zig Ableger-Seiten davon, ich glaub da wird man mit Klagen gar nicht mehr fertig, das ist groß organisierte Vorgehensweise von Impfgegner

- What can you say about next programs? flu, shingles? What is mRNA bringing to the table? There are more than 10 infectious vaccine programs we are working on. Some of them with Pfizer. We are using different platforms for modified and self-amplifying mRNA. HIV for example. Tuberculosis: current vaccines are not very good - mRNA could bring a huge progress here. Malaria.. We are going broad here. In case of shingles, there is a very high incidence. We think that our technology could potentially improve the safety profile in comparison to existing vaccine. We are aiming (together with Pfizer) for shingles vaccine already this year [Zusatz: Unklar, worauf sich “already this year bezog” - wahrscheinlich eher Trial Start oder Daten read-out, aber noch nicht ein fertiger Impfstoff] - What about bacterial targets? There is a broad applicability. We can reprogram the immune system. This is not exclusive for viruses. Not only by way of vaccines. There is a disruptive potential. Using mRNA to reprogram. We can be active in both. We can target certain bacterial infections. - When can we see more data? We are expecting multiple readouts, mostly in the second half of this year. Big readouts: INeST - FixVac - Car-T Cells - GenMap …

Simultan-Mitschrieb der SVB Leerink Konferenz vom 16.2.22 um 14:40 Uhr (https://wsw.com/webcast/svbleerink67/bntx/2681400): - Vaccine for ages 6 months up to 5 year olds: the date was shifted for a week or two, the trial is ongoing, we are looking at a 2 or 3 dose regimen, 3 microgram each, there is no major delay, we will have more clarity in the next 1 or 2 months - Broader booster: multiple trials are in progress specific for delta, alpha, beta variants, etc.; for Omikron, we are looking at one or two or three omikron doses - Omikron data is expected in late March or early April, pending regulatory process - Third booster of Wildtype is still leading to a broader protection - Omikron is significantly different than other variants: in this case, we believe there will be a higher protection from a variant specific approach - We are seeing an abundance of new variants - it’s still too early to determine whether we will achieve a protection against other variants but data is suggesting a better protection with Omikron vaccine - multiple vaccinations may be required against Omikron - T cell response is important, neutralising antibody response tends to vain over time, so both is important - will more than 1 boost be required against Omikron? That’s right. We are starting to develop omikron specific antibody titers. We may require multiple vaccinations to get a comparably high antibody response - Comparison to wild type; we should be able to re-train the immune system - let’s look at that from a revenue perspective: for how long will we require annual boosts? Antibody response vains within a year. That’s one data point for a regular booster. The frequency of boosters depends first of all on the evolution of variants. Another factor is the durability of protection - because of longer T-cell response an annual booster may avoid deaths and hospitalizations but for protection against infection a more frequent booster may be useful - can you target something different than only the spike protein to get a longer durability? Comparison to other vaccines with up to 10 year protection? We don’t know yet. Multiple different approaches. Short term, mid term, long term view as we learn more - What can you say about the infrastructure beyond CoVid-19? we do believe there will be a long term market! We have a pretty rich pipeline and are planning to bring additional products. Oncology pipeline. Multiple additional vaccine programs. That’s just the beginning. We want to advance them to the market quickly. Unlike existing vaccine technology platforms, the mRNA platform is very flexible and very capital efficient. We will produce 4 billion doses this year and are looking to expand capacity. We are also creating sustainable solutions for Africa - there is interest among governments and NGOs to prepare better solutions: we are working on a rapid pandemic response, on an early warning system for CoVid and on rapid local responses - what about the China process? We are still engaged. It is true that there are no approvals yet. It is a dynamic environment. We continue to be proactive and address any questions. We continue to work with regulators to try to open up that market.